GlassScriptPhysician profile
Vaibhav Mehendiratta
NPI 1306053160
$11,887.70
in general payments reported to CMS, 2019-2025
40 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $392 · 2021: $294 · 2022: $6,313 · 2023: $1,249 · 2024: $1,185 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129 · Travel and Lodging: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.81 |
| Travel and Lodging | $111.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,084.19 | 2022-2025 | Resolution 360 Clip, Resolution 360 Ultra Clip, General - Therapies |
| Abbvie INC. | $1,206.85 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $914.11 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $891.99 | 2019-2025 | Entyvio, Eohilia, Livtencity |
| Janssen Biotech, INC. | $456.76 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $260.98 | 2019-2025 | |
| Fujifilm Healthcare Americas Corporation | $253.47 | 2020-2024 | Fujifilm, Utaswako Afp-L3 |
| Ironwood Pharmaceuticals, INC | $208.62 | 2019-2025 | Linzess |
| Celgene Corporation | $141.59 | 2022-2024 | Zeposia |
| Genzyme Corporation | $116.57 | 2019-2025 | |
| Olympus America INC. | $111.75 | 2023 | |
| Cook Medical LLC | $106.23 | 2022 | |
| Allergan, INC. | $93.34 | 2019 | |
| Ardelyx, INC. | $87.00 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $83.48 | 2022-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $74.27 | 2025 | Barrx |
| Ferring Pharmaceuticals INC. | $72.13 | 2022-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $60.79 | 2019 | |
| Intercept Pharmaceuticals, INC. | $58.18 | 2019-2025 | |
| Lilly USA, LLC | $57.93 | 2024-2025 | Omvoh |
| Shionogi INC | $51.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.47 | 2023-2025 | Dupixent |
| Merit Medical Systems INC | $48.33 | 2020 | |
| Qol Medical, LLC | $41.33 | 2025 | Sucraid |
| Ucb, INC. | $36.60 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.75 | 2019 | |
| Novo Nordisk INC | $34.23 | 2025 | Wegovy |
| Evoke Pharma, INC. | $29.99 | 2023-2024 | Gimoti |
| Creo Medical INC. | $28.87 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.28 | 2023 | Givlaari |
| Fresenius Kabi USA, LLC | $23.17 | 2024 | Idacio |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $21.96 | 2024 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $19.94 | 2022 | |
| Aimmune Therapeutics, INC. | $19.70 | 2024 | |
| Amag Pharmaceuticals, INC. | $17.04 | 2020 | |
| Dova Pharmaceuticals | $16.04 | 2019 | |
| Alfasigma USA, INC. | $15.00 | 2020 | |
| Shire North American Group INC | $14.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaibhav Mehendiratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.